Inventor · disambiguated record
Peter Carlsen
Also filed as: CARLSEN PETER · CARLSEN PETER NIELS
7 granted patents·15 pending applications·0 citations·filing 2019–2025
68Inventor score
Top patents by PatentIndex Score
22 records- 0179US12378243B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2024·Granted Aug 5, 2025·0 cites·34 claims
- 0276US2025041310A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 0375US2024360140A1Fused pyrazine derivatives as a2a / a2b inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 0475US2025059293A1Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2024·Application pending·0 cites
- 0574US2025368641A1Quinoline compounds as inhibitors of krasINCYTE CORP·Filed 2025·Application pending·0 cites
- 0672US2024343742A1Vinyl imidazole compounds as inhibitors of krasINCYTE CORP·Filed 2024·Application pending·0 cites
- 0769US2025188073A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2024·Application pending·0 cites
- 0867US11999740B2Fused pyrazine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2021·Granted Jun 4, 2024·0 cites·36 claims
- 0965US2022213112A1Pyrrole tricyclic compounds as a2a / a2b inhibitorsINCYTE CORP·Filed 2021·Application pending·0 cites
- 1064US2024368156A12-azabicyclo[2.2.1]heptane kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1162US12060433B2CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapyINCYTE CORP·Filed 2020·Granted Aug 13, 2024·0 cites·39 claims
- 1262US2024358702A1Cyclic urea kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1361US11999752B2Vinyl imidazole compounds as inhibitors of KRASINCYTE CORP·Filed 2021·Granted Jun 4, 2024·0 cites·38 claims
- 1461US2021205311A1Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 InhibitorsINCYTE CORP·Filed 2020·Application pending·0 cites
- 1560US11220510B2Pyrrole tricyclic compounds as A2A / A2B inhibitorsINCYTE CORP·Filed 2019·Granted Jan 11, 2022·0 cites·2 claims
- 1660US2024390340A1Pyrrolidine kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1759US12030883B2Hetero-tricyclic compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Jul 9, 2024·0 cites·39 claims
- 1858US2022233529A1Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodiesINCYTE CORP·Filed 2021·Application pending·0 cites
- 1958US2021269434A1Tricyclic compounds as inhibitors of krasINCYTE CORP·Filed 2021·Application pending·0 cites
- 2057US12441742B2Naphthyridine compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Oct 14, 2025·0 cites·28 claims
- 2157US2023226040A1Combination therapy comprising an fgfr inhibitor and a kras inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 2232US2022177508A1C10-Cyclic Substituted 13-Membered Macrolides and Uses ThereofZIKANI THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Carlsen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →